Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CEO Sean Nolan sold 136,789 shares of the stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total value of $649,747.75. Following the completion of the transaction, the chief executive officer owned 2,949,569 shares of the company’s stock, valued at $14,010,452.75. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA opened at $4.57 on Friday. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The stock’s fifty day moving average is $5.11 and its two-hundred day moving average is $4.09. The company has a market capitalization of $1.25 billion, a P/E ratio of -13.85 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

A number of large investors have recently modified their holdings of TSHA. AQR Capital Management LLC boosted its holdings in Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after purchasing an additional 82,545 shares during the period. Chicago Partners Investment Group LLC increased its holdings in Taysha Gene Therapies by 40.5% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 163,766 shares of the company’s stock worth $378,000 after purchasing an additional 47,201 shares during the period. Ethic Inc. acquired a new stake in Taysha Gene Therapies in the 2nd quarter valued at about $67,000. Tybourne Capital Management HK Ltd. raised its position in Taysha Gene Therapies by 10.7% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock valued at $9,459,000 after purchasing an additional 395,000 shares in the last quarter. Finally, May Hill Capital LLC purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $37,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TSHA. The Goldman Sachs Group set a $11.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. JMP Securities set a $8.00 target price on Taysha Gene Therapies in a research report on Wednesday, November 5th. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Wells Fargo & Company increased their target price on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.